Abilify (Aripiprazole)

Aripiprazole is pronounced: ah-rih-PIP-rah-zole. Breaking it down syllable by syllable: a-ri-pip-ra-zole. The emphasis falls on the third syllable: “PIP.” The brand name Abilify is pronounced ah-BIL-ih-fy, which most people find easier to say.

Abilify (aripiprazole) is FDA-approved to treat Bipolar I Disorder (acute manic or mixed episodes and maintenance), Major Depressive Disorder (as an adjunct to antidepressants), schizophrenia, and irritability associated with Autism Spectrum Disorder. It may also be prescribed off-label for conditions such as OCD, PTSD, borderline personality disorder, and schizoaffective disorder.

Yes. Abilify is a second-generation antipsychotic (SGA), also called an atypical antipsychotic. Unlike first-generation antipsychotics, SGAs are designed to reduce the risk of certain short-term and long-term movement-related side effects while treating symptoms of psychosis, mood instability, and related conditions.

No. Abilify (aripiprazole) is not a selective serotonin reuptake inhibitor (SSRI). It is a second-generation antipsychotic that works differently from SSRIs like Lexapro (escitalopram) or Prozac (fluoxetine). However, Abilify is sometimes prescribed alongside an SSRI as an adjunct treatment for Major Depressive Disorder.

Aripiprazole (Abilify) works by affecting chemical messengers in the brain called neurotransmitters, primarily dopamine and serotonin.

When dopamine activity in certain areas of the brain is too high, it can cause symptoms like hallucinations (seeing or hearing things that are not there) or delusions (believing things that are not true). Dopamine is also involved in muscle movement, so when dopamine activity in certain areas of the brain is too low it can affect how the body moves. Both dopamine and serotonin are thought to play key roles in regulating mood.

Aripiprazole works as a partial agonist at dopamine D2 and serotonin 5-HT1A receptors, and as an antagonist at serotonin 5-HT2A receptors. In plain terms, a receptor antagonist full blocks a receptor. However, a partial agonist partially activates receptors, rather than fully blocking or fully stimulating them, acting like a dimmer switch rather than an on/off switch. This combination of actions by aripiprazole helps stabilize activity in the brain circuits linked to mood, perception, and behavior, which is why it can be effective across several different conditions.

Like all medicines, aripiprazole can cause side effects, although not everyone gets them.

Common side effects (may affect up to 1 in 10 individuals):

• Difficulty sleeping (insomnia). This usually improves over time. If you take aripiprazole at night, switching to a morning dose may help. Avoid large meals, alcohol, caffeine, or screen time close to bedtime. If sleep does not improve, speak with your clinician.
• Feeling anxious or restless (akathisia). This may or may not get better over time. If it persists for more than a few days, contact your clinician, because dose reduction or stopping the medication may be needed.
• Headache. This typically improves within a few days. Rest and staying hydrated can help. Speak with your clinician if headaches are severe or last more than a week.
• Nausea or vomiting. This typically improves within a few days. Stick to simple meals and avoid rich or spicy food. Taking aripiprazole with food or a snack may help. If vomiting persists, contact your clinician before taking any over-the-counter remedies.
• Indigestion. This typically improves within a few days. Avoiding rich or spicy foods while taking this medication may help.
• Constipation. This typically improves within a few weeks. Increasing fiber intake (fruits, vegetables, whole grains) and drinking plenty of water can help. Regular exercise may also make a difference.
• Feeling sleepy or sedated. Avoid driving or operating machinery if this occurs. Drowsiness often decreases as your body adjusts to the medication. If you take aripiprazole in the morning, switching to an evening dose may help. If sedation persists after a few weeks, speak with your clinician.
• Blurred vision. Speak with your clinician if this occurs.

For some individuals, many side effects are mild and improve with time. Speak with your clinician if a side effect is persistent or significantly affecting your daily life.

Serious side effects — contact your clinician promptly if you experience:

• Increased thirst, frequent urination, fatigue, or unexplained weight loss — these may be signs of high blood sugar or diabetes
• Movement difficulties, including feeling the need to move constantly, muscle stiffness (including tongue), or jerky movements
• Uncontrollable movements of the mouth, tongue, or limbs
• Twisting movements of the body or limbs (such as the neck turning to one side or feet turning inward) — this may indicate a condition called dystonia
• Sudden onset of confusion, fever, muscle rigidity. If this occurs it is considered a medical emergency and you should go directly to an emergency room, do not wait for a response from your psychiatric clinician.

Weight gain is possible with Abilify, though it is generally considered less pronounced than with other second-generation antipsychotics such as olanzapine (Zyprexa) or quetiapine (Seroquel). Individual responses vary based on dose, duration of use, and other factors. Discuss any concerns with your clinician.

Initial improvements may appear within 1–2 weeks for conditions such as acute mania or agitation. For depression (as an adjunct) or schizophrenia, full benefits may take 4–6 weeks or longer. Consistency in taking the medication as prescribed is important during this period.

No. Abilify (aripiprazole) is not a controlled substance. It is a prescription medication but does not carry the same regulatory restrictions as substances with abuse potential.

Abilify is not FDA-approved for generalized anxiety disorder or other primary anxiety disorders. However, it is sometimes used off-label as an adjunct in conditions where anxiety is a component, such as PTSD or OCD. Talk with your clinician about whether it is appropriate for your specific situation.

Aripiprazole has a long half-life—approximately 75 hours for the parent compound and about 94 hours for its active metabolite dehydro-aripiprazole. This means it can remain detectable in the body for approximately two weeks after the last dose. The long half-life can be advantageous in some clinical situations, as missed doses may have less immediate impact.

Both Abilify (aripiprazole) and Rexulti (brexpiprazole) are second-generation antipsychotics and partial dopamine D2 agonists. Rexulti was developed with a similar mechanism but is designed to have a more favorable tolerability profile, particularly for akathisia (restlessness). Both are FDA-approved as adjunctive treatments for MDD, but their approved indications and specific side effect profiles differ. Your clinician will consider your history and treatment goals when recommending one over the other.

Abilify (aripiprazole) and Seroquel (quetiapine) are both second-generation antipsychotics approved for bipolar disorder and schizophrenia, but they work differently. Seroquel is a full antagonist at multiple receptors and has stronger sedating effects, often making it useful for sleep disturbances associated with these conditions. Abilify is a partial agonist and is generally less sedating. Seroquel is also associated with more significant weight gain and metabolic effects. The right choice depends on your symptoms and side effect profile.

Both Abilify (aripiprazole) and risperidone are second-generation antipsychotics, but risperidone acts primarily as a dopamine and serotonin receptor antagonist, while Abilify is a partial dopamine agonist. Risperidone may be more effective for certain psychotic symptoms but carries a higher risk of movement-related side effects and elevated prolactin levels. Abilify tends to have a lower risk of these side effects. Individual response varies, and a clinician will help determine the best fit.

Abilify (aripiprazole) and Latuda (lurasidone) are both atypical antipsychotics used for bipolar disorder and schizophrenia. Latuda has a lower risk of weight gain and metabolic effects and must be taken with food (at least 350 calories) to be properly absorbed. Abilify has a longer half-life and more FDA-approved indications, including as an adjunct for MDD. The choice between them depends on individual clinical factors, including your metabolic risk profile and condition being treated.

Abilify (aripiprazole) and Vraylar (cariprazine) are both partial dopamine D2/D3 agonists with similar mechanisms. Vraylar has a high affinity for the D3 receptor, which may make it particularly effective for bipolar depression, an indication for which it has FDA approval and Abilify does not. Both medications require dose titration and have relatively long half-lives. Your clinician will assess which is more appropriate based on your specific diagnosis and history.

Abilify is not known for being addictive when taken as prescribed by a clinician. It is not a controlled substance and does not have a reputation for causing chemical dependence. However, stopping it suddenly can cause withdrawal-like effects in some individuals.

The cost of Abilify varies depending on whether you are prescribed the brand-name medication or the generic version, aripiprazole, and the dosage form.

• Generic aripiprazole (oral tablet): As of publication date, prices start at approximately $6.68–$11.92 for a 30-tablet supply, depending on dosage strength. Generic oral solution (1 mg/mL) starts at around $226.55 for 150 mL. Generic orally disintegrating tablets start at approximately $387.04 for 30 tablets.
• Brand-name Abilify (oral tablet): As of publication date, prices start at approximately $578.16 for 30 tablets for lower doses (2–15 mg), and $814.30 for 30 tablets at higher doses (20–30 mg).

If you have insurance, your out-of-pocket cost will depend on your supporting diagnosis and plan type (e.g., commercial, Medicare, Medicaid) and may include a copay or coinsurance.

Abilify is FDA-approved for certain indications in younger individuals, including schizophrenia (adolescents aged 13–17), bipolar I disorder (aged 10–17), and irritability associated with autism spectrum disorder (children aged 6–17). All antidepressant and second generation antipsychotic medications carry an FDA warning about increases in suicidal ideation for teenagers and young adults. Abilify and any antipsychotic should only be taken as and when prescribed by an appropriately licensed medical professional.

Try to avoid alcohol while on Abilify. Alcohol may worsen side effects such as dizziness, drowsiness, and impaired judgment. Second-generation antipsychotics can enhance the sedating and intoxicating effects of alcohol. Alcohol may also interfere with the effectiveness of the medication and worsen the underlying condition being treated.